The receipt panel recorded $14.76, while parts of the original model text used $14.55 without a separate quote timestamp. This revision uses $14.76 consistently for its arithmetic. Compared with the $9.16 20-day average, that is a 61.1% extension. It is also 44.7% above the saved $10.20 mean analyst target. Neither calculation predicts the direction of the next session.
RSI of 85.0 described an unusually strong run in the saved series. Such strength can persist, and it can reverse abruptly. It does not identify exhausted buyers or trapped short sellers. The three WAIT votes and one CONDITIONAL vote reflected that tension, but model voting is not a calibrated probability of success.
For a clinical-stage company, trial results, regulatory milestones, cash requirements and financing terms can dominate a chart. A reference to ASCO 2025 is historical context, not a fresh June 2026 catalyst. A useful catalyst calendar must distinguish a company-confirmed date from an estimate or an event-count threshold. This revision makes no clinical-success forecast and imports no later trial outcome into the original setup.
The archived conditional vote required a break above $15.88. That is a prospective confirmation level, whereas the $9.16 moving average, $7.07 support and $6.93 structural floor describe increasingly distant downside references. Waiting for a move back toward an analyst target is a separate thesis. Combining those alternatives into a single “one level” instruction hid the amount of price risk involved.
A new review should establish the latest company announcement, the next verified milestone, available cash and any financing changes, then match the option expiry to that horizon if options are considered. The recorded $135K net flow premium and a gamma concentration near $15 do not prove forced buying or a cap on losses. Missing contract-level evidence should remain missing, not be supplied by an appealing story.
Editorial review: 2026-10-06. Unified price arithmetic, corrected the interpretation of the mean target, separated historical ASCO context from new catalysts, and removed squeeze and gamma certainty.
The market figures above come from the original saved article snapshot. Linked primary documents support the specific corporate facts discussed, not the historical quote or the model verdict.
No later price outcome is used to grade or improve the historical model vote. The original stored article remains preserved for audit.